Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug
Minerva Neurosciences’ stock chart went vertical on Tuesday after the biotech announced an expansive financing deal that effectively triples the company’s market capitalization overnightmarketbeat.com. In pre-market trading on Oct. 21, NERV stock jumped as much as 160% on the newsgurufocus.com. The shares opened around $6–7 and oscillated near those levels through the day, ultimately marking a 52-week high of $6.97marketbeat.com. By comparison, NERV had traded as low as $1.15 within the past yearmarketbeat.com, reflecting both the dramatic rebound and the extreme volatility inherent in this micro-cap biotech.
